Zhongguo Zhong Yao Za Zhi. 2024 Sep;49(17):4805-4811. doi: 10.19540/j.cnki.cjcmm.20240429.501.
High altitude polycythemia(HAPC) is one of the most common chronic high-altitude diseases and a prominent public health issue in the Qinghai-Xizang Plateau region of China. Tibetan medicine has provided a safe and effective treatment approach for HAPC, but there is currently no expert consensus on Tibetan medicine diagnosis and treatment for the disease. This consensus followed the principles of evidence-based medicine and learned the procedure and methods of Technical specifications on developing expert consensus for clinical practice guideline in traditional Chinese medicine recommended by China Association of Chinese Medicine. Five clinical issues were identified through literature search, expert interviews, clinical research, and conference consensus. The PICO principle was used for evidence retrieval, screening, and synthesis, and the opinions of experts on high-altitude diseases and cardiovascular and cerebrovascular diseases from major Tibetan medical institutions in China, as well as some traditional Chinese medicine(TCM), western medicine, and evidence-based experts, were widely solicited. Recommendations and consensus suggestions were formed through one expert consensus meeting and two rounds of Delphi expert questionnaire surveys. The consensus included disease diagnosis, etiology and pathogenesis, syndrome classification, clinical treatment, outcome evaluation, prevention and care, and other contents. Therapies for HAPC included Tibetan medicine treatments based on syndrome differentiation, single formula or patent medicine, and external treatment. Each treatment had corresponding levels of evidence and recommendations. This consensus was guided by solving clinical problems, combining disease diagnosis and syndrome differentiation and highlighting the characteristics and advantages of Tibetan medicine, with a view to promoting the standardization of Tibetan medicine diagnosis, treatment, and research on HAPC and improving the level of prevention and treatment.
高原红细胞增多症（HAPC）是最常见的慢性高原病之一，也是中国青藏高原地区一个突出的公共卫生问题。藏医为HAPC提供了安全有效的治疗方法，但目前对于该病的藏医诊疗尚无专家共识。本共识遵循循证医学原则，借鉴了中华中医药学会推荐的《中医临床诊疗指南制定专家共识技术规范》的程序和方法。通过文献检索、专家访谈、临床研究和会议共识确定了五个临床问题。采用PICO原则进行证据检索、筛选和合成，广泛征求了国内主要藏医机构以及部分中医、西医和循证医学专家对高原病及心脑血管疾病的意见。通过一次专家共识会议和两轮德尔菲专家问卷调查形成了推荐意见和共识建议。该共识涵盖疾病诊断、病因病机、证候分类、临床治疗、疗效评价、预防调护等内容。HAPC的治疗方法包括辨证论治的藏医治疗、单方或成药以及外治疗法。每种治疗方法都有相应的证据级别和推荐意见。本共识以解决临床问题为导向，将疾病诊断与辨证相结合，突出藏医特色与优势，旨在促进HAPC藏医诊疗及研究的规范化，提高防治水平。
